Windlas Biotech Limited (WINDLAS) fundamentals
Windlas Biotech Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as WINDLAS (ISIN INE0H5O01029). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Windlas Biotech Limited does
Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.
Valuation and market data
| Last close | ₹1129.50 |
|---|---|
| Market capitalisation | ₹2,376 crore |
| Enterprise value | ₹2,381 crore |
| P/E (TTM) | 35.76 |
| Price to book | 4.09 |
| Price to sales (TTM) | 1.47 |
| Book value per share | ₹276.17 |
| Dividend yield | 55.78% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Aug 16 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹922 crore | ₹87 crore | ₹66 crore | 31.59 |
| Mar 2025 | ₹778 crore | ₹79 crore | ₹61 crore | 29.03 |
| Mar 2024 | ₹644 crore | ₹77 crore | ₹58 crore | 27.95 |
| Mar 2023 | ₹523 crore | ₹57 crore | ₹43 crore | 19.71 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 63.3% |
|---|---|
| Foreign institutions (FII) | 2.0% |
| Mutual funds | 5.8% |
| Other domestic institutions | 4.1% |
| Retail and others | 24.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.